Clinical Research Directory

Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP)

Sponsor: Keymed Biosciences Co.Ltd

Summary

This is a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and initial efficacy of CM313 (SC) injection in patients with primary immune thrombocytopenia.

Official title: A Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Initial Efficacy of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia

Key Details

Conditions

Interventions

Locations (1)